Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer
In December, Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) reported top-line data from 10 evaluable patients with platinum-sensitive or -resistant ovarian cancer in the first dose cohort of a Phase Ib trial showing that subcutaneous DPX-Survivac plus twice-daily 100 mg oral epacadostat (INCB24360) and low-dose cyclophosphamide led to an overall response rate (ORR) of 30%, including three partial responses, plus four cases of stable disease. The combination was well tolerated.
Preliminary data from the first three evaluable patients in the second dose cohort showed that DPX-Survivac plus twice-daily 300 mg epacadostat and low-dose cyclophosphamide led to two cases of stable disease. Updated data from the second dose cohort are expected this half...